Suppr超能文献

放射性诱发的乳腺血管肉瘤——单机构经验

Radiation-Induced Breast Angiosarcoma-A Single-Institution Experience.

作者信息

Buta Marko, Santrac Nada, Zegarac Milan, Goran Merima, Jeftic Nikola, Savkovic Nevena, Raketic Jovan, Pavlovic Saska, Zivkovic Ognjen, Rankovic Aleksandar, Markovic Ivan

机构信息

School of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.

Surgical Oncology Clinic, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.

出版信息

Diagnostics (Basel). 2024 Oct 18;14(20):2326. doi: 10.3390/diagnostics14202326.

Abstract

: Radiation-induced breast angiosarcoma (RIBAS) is a rare adverse event associated with postoperative breast irradiation. The data from the literature indicate that RIBAS occurs in less than 0.3% of patients treated with adjuvant radiotherapy for breast cancer. Given the rarity, diverse clinical presentation, poor prognosis, and lack of consensus on the management, this study aimed to present experiences of our specialized cancer center with RIBAS, in terms of the incidence, presentation, management, and outcomes. : We reviewed the medical records of 10,834 breast cancer patients treated at the Institute for Oncology and Radiology of Serbia between January 2013 and June 2024 to detect patients that had breast-conserving surgery, followed by postoperative irradiation, and developed angiosarcoma in the irradiated area at least 3 years after radiotherapy, without distant metastases. The incidence, latency period, management, and treatment outcomes were analyzed. : A total of nine female patients with RIBAS were identified and included in this study. The median age at RIBAS diagnosis was 64 years (range: 36-68), with a median latency of 64 months (95% CI > 57) from irradiation to diagnosis. The mean tumor size was 55 mm (SD 32.78). Patients were followed for a median of 30 months (range: 7-40) after initial RIBAS surgery. Local recurrence occurred in seven patients (77.8%), with five undergoing re-do surgery with curative intent. Three patients developed distant metastases during follow-up. The median overall survival (OS) was 31 months (95% CI > 30), with a 3-year survival rate of 15.2% (95% CI 2.5-91.6%). The median local recurrence-free interval was 10 months (95% CI > 3). Median OS after RIBAS local recurrence and after breast cancer treatment was 17 months (95% CI > 15) and 108 months (95% CI > 88), respectively. : RIBAS is a rare but increasingly prevalent adverse event associated with BC irradiation, marked by an aggressive disease course and high relapse rates. Awareness, prompt diagnosis, and a radical surgical approach with wide clear margins are critical for improving patients' outcomes.

摘要

放射性诱导的乳腺血管肉瘤(RIBAS)是一种与乳腺癌术后放疗相关的罕见不良事件。文献数据表明,RIBAS在接受辅助放疗的乳腺癌患者中发生率低于0.3%。鉴于其罕见性、多样的临床表现、不良预后以及治疗方面缺乏共识,本研究旨在介绍我们专业癌症中心在RIBAS的发病率、表现、治疗及结局方面的经验。

我们回顾了2013年1月至2024年6月期间在塞尔维亚肿瘤与放射研究所接受治疗的10834例乳腺癌患者的病历,以找出那些接受了保乳手术、术后放疗且在放疗后至少3年在放疗区域发生血管肉瘤且无远处转移的患者。分析了发病率、潜伏期、治疗及治疗结局。

本研究共纳入9例RIBAS女性患者。RIBAS诊断时的中位年龄为64岁(范围:36 - 68岁),从放疗到诊断的中位潜伏期为64个月(95%置信区间>57)。平均肿瘤大小为55 mm(标准差32.78)。患者在首次RIBAS手术后中位随访30个月(范围:7 - 40个月)。7例患者(77.8%)发生局部复发,其中5例接受了旨在治愈的再次手术。3例患者在随访期间发生远处转移。中位总生存期(OS)为31个月(95%置信区间>30),3年生存率为15.2%(95%置信区间2.5 - 91.6%)。RIBAS局部复发后的中位无局部复发生存期为10个月(95%置信区间>3)。RIBAS局部复发后和乳腺癌治疗后的中位OS分别为17个月(95%置信区间>15)和108个月(95%置信区间>88)。

RIBAS是一种与乳腺癌放疗相关的罕见但日益普遍的不良事件,其病程侵袭性强且复发率高。提高认识、及时诊断以及采用具有广泛切缘的根治性手术方法对于改善患者结局至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ba6/11506978/9ee680a2cc1f/diagnostics-14-02326-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验